- TLDR Biotech
- Archive
- Page 6
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | January 9 - 12, 2025
$800M in company launches (5 in all!), Pfizer's subcutaneous PD-1 inhibitor succeeds in bladder cancer Ph3, Eli Lilly & a16z launch $500M biotech venture fund, Metsera files for IPO to fund obesity ambitions, Biogen makes $442M bid for partner Sage Therapeutics, AbbVie takes a $3.5B write-down after surprise Cerevel asset Ph2 failure + 40 more stories
Biotech & Pharma Updates | January 8 - 9, 2025
Massive $410M Series A for just-launched obesity biotech Verdiva Bio, A2 Biotherapeutics $80M Series C for “logic-gated” cell therapies, GSK's rumored $1B IDRx takeover might be announced at JPM next week, Synaffix & Boehringer Ingelheim partner to develop next-gen ADCs, Intellia Therapeutics cuts 27% of workforce, Vanda Pharmaceuticals blasts FDA leadership (again) + 32 more stories
Biotech & Pharma Updates | January 7 - 8, 2025
Tenvie Therapeutics launches with $200M and neurological treatment assets acquired from Denali Therapeutics, Aspect Biosystems $115M Series B to fuel bioprinting tissue tech ambitions, Novo Nordisk & Valo Health expand $4.6B partnership to develop cardiometabolic drugs targeting obesity and diabetes, Galapagos splits in half (with 40% workforce reduction) + 32 more stories
Biotech & Pharma Updates | January 6 - 7, 2025
Sana Biotechnology pushed the T1D boundary with sustained insulin delivery from implanted islet cells without immunosuppression, Avenzo Therapeutics in-licenses DualityBio's AVZO-1418/DB-1418 solid tumor-targeting bispecific, Aviceda Therapeutics $207.5M Series C fuels geographic atrophy ambitions into Ph3, Variant Bio and Novo Nordisk bet on novel drug discoveries through genetically diverse populations, Calico Life Sciences & Denali Therapeutics both face ALS clinical trial failures + 36 more stories
Biotech & Pharma Updates | January 5 - 6, 2025
FDA publishes new draft guidance regarding confirmatory trials in accelerated approvals, Amgen's lung cancer bispecific tarlatamab nabs UK conditional marketing nod, Merck & Co. buys Ireland-based Wuxi Biologics vaccine site, Aditum Bio closes $428M Fund III, Velia Therapeutics microprotein dreams go bust two years after a $55M Series A + 26 more stories
Biotech & Pharma Updates | January 1 - 5, 2025
Regeneron acquires Oxular and gets hands on novel ocular drug delivery tech, BMS's Opdivo lands new approval for subcutaneous version, Roche in-licenses Innovent ADC in up to $1B deal, General Proximity launches with $16M to go after "undruggable" disease-linked proteins, Neumora stock collapses after navacaprant Ph3 failure in major depressive disorder + 31 more stories
Biotech & Pharma Updates | December 18 - 19, 2024 (see you in 2025 🎄)
Ottimo Pharma's CEO ready to "have some fun" with $140M Series A, BMS buys two preclinical Alzheimer's antibodies from BioArctic, KdT Ventures launches a currently unnamed rare disease start-up powered by an NGM Bio asset, US government nears shutdown as PBM reform thrown to the wayside + 31 more stories
Biotech & Pharma Updates | December 17 - 18, 2024
Novartis & AbbVie score a 340B win in West Virginia, FDA approves Mesoblast's allogeneic mesenchymal stromal cell therapy (a US first), Novartis and BioAge Labs partner on age-related disease drug discovery, AstraZeneca likely taking a sales hit in China amid employee investigations + 36 more stories
Biotech & Pharma Updates | December 16 - 17, 2024
Sandoz pays $275M to settle generic price-fixing litigation, Pfizer forecasts a more stable & upbeat 2025, Akamis Bio's $60M raise fuels oncolytic gene therapy ambitions, The Big Apple gets a CGT manufacturing hub, PBMs (unsurprisingly) fight back against PBM reform + 26 more stories
Biotech & Pharma Updates | December 15 - 16, 2024
Novo Holdings & Catalent deal full steam ahead after FTC ok, Promise Bio launches with AI-driven precision medicine for autoimmune diseases ambitions, Candid Therapeutics signs on trio of bispecific R&D deals, Roche discontinues Ph3 gene therapy asset development + 30 more stories
Biotech & Pharma Updates | December 12 - 15, 2024
AbbVie to acquire Nimble Therapeutics for $200M, Novavax lands $50M milestone payment related to Sanofi-partnered pediatric COVID-19 vaccine, Turn Therapeutics $75M investment to fuel advanced wound and dermatology ambitions, McKinsey agrees to $650 settlement in Purdue opioid case + 29 more stories
Biotech & Pharma Updates | December 11 - 12, 2024
Investors sue BMS on alleged reneging on milestone payments, Novo Nordisk's Ozempic lands kidney disease-related label expansion in the EU, Expression Therapeutics has “promising” Ph1 hemophilia A gene therapy data, Keros Therapeutics stock plummets on PAH clinical trial holds due to pericardial effusion cases + 32 more stories